The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.
about
Chronic over-nutrition and dysregulation of GSK3 in diseasesInsulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer RiskBroad Spectrum Anticancer Activity of Myo-Inositol and Inositol HexakisphosphateChemoprevention of lung cancer: prospects and disappointments in human clinical trialsReduction-oxidation pathways involved in cancer development: a systematic review of literature reviews.The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis.Inhibition of vinyl carbamate-induced pulmonary adenocarcinoma by indole-3-carbinol and myo-inositol in A/J miceOptimizing mouse models for precision cancer prevention.Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination.The BATTLE to personalize lung cancer prevention through reverse migration.Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD SmokersSOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis.Airway PI3K pathway activation is an early and reversible event in lung cancer development.A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease.Myo-inositol reduces β-catenin activation in colitis.Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer.
P2860
Q26738964-545CB2AE-A1FA-4E56-AF8B-3E02A16A1CC2Q28072521-D262B7E5-FB26-491E-9FE8-0B401595411DQ28078208-C57A4D1F-0215-4C86-9D72-EDBD7990A691Q28386632-452C0F57-E270-4294-9E26-13C1ECC375D3Q30234584-9F712C8F-6BBD-45C7-9F12-594B2B4D9ABCQ33584802-68DC77C2-21B6-4030-A995-D0A65FD6B8C8Q33615285-A37CF533-6866-40CC-835D-18481244FB4FQ33919192-C259B598-E6A4-4A57-AFDB-E4C3109EA52AQ34094986-A208F7A7-0B44-466F-ADC5-8CA3E1AC607EQ35208501-AED92B0E-23EC-43F2-9979-5C9D5CD0373BQ35870656-A770AAB0-1D03-41B7-8D47-500037138770Q36202378-AF6914C8-45B9-4205-A46D-5AF57C1DC7A5Q36959707-FAD8FF0D-B44A-49EB-9038-8EF8C99DA1E0Q37470702-55A527A7-A684-404E-8748-DA9682199FF7Q38879505-C3DB2F05-ACAB-4150-B8ED-098F0A452D3EQ41191056-656838B7-311A-4287-97BE-0DC704CD21C8Q42513461-8D3E0A02-724D-41E8-B01E-F6677C6574B1Q44798575-D356EB41-6AB6-40CE-954F-7C0F6624FAFA
P2860
The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@en
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@nl
type
label
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@en
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@nl
prefLabel
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@en
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@nl
P2093
P2860
P1476
The chemopreventive agent myoi ...... al lesions from heavy smokers.
@en
P2093
Joell J Gills
Phillip A Dennis
Regan M Memmott
Stephen Lam
P2860
P304
P356
10.1158/1940-6207.CAPR-08-0209
P577
2009-03-31T00:00:00Z